Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 6/20 | 0.57 |
| ▸ | CASP1 | P29466 | 4/20 | 0.57 |
| ▸ | CASP9 | P55211 | 4/20 | 0.57 |
| ▸ | CASP6 | P55212 | 2/20 | 0.57 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.57 |
| ▸ | CASP4 | P49662 | 1/20 | 0.57 |
| ▸ | CASP5 | P51878 | 1/20 | 0.57 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 6/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | REN | P00797 | 2/20 | 0.51 |
| ▸ | CASP7 | P55210 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20257265 | 1.00 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL21481085 | 1.00 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL23133285 | 1.00 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL23133287 | 1.00 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL28714127 | 0.94 | REN (0.52) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL29449496 | 0.94 | REN (0.52) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL17814784 | 0.94 | REN (0.52) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL20257264 | 0.94 | CASP3 (0.56) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL23133258 | 0.92 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 | |
| SCHEMBL23133257 | 0.92 | CASP3 (0.57) | CASP3CASP1CASP9CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118320091-A | Compositions of caspase inhibitors and methods of use thereof | 香港大学 | 2024-07-12 | — | — | CN | claimed |
| US-20240115649-A1 | CASPASE INHIBITION TO ENHANCE REGENERATION AND REPAIR AFTER SKIN OR GUT INJURY AND TO TREAT BACTERIAL OR VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | claimed |
| US-20240024405-A1 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2024-01-25 | — | — | US | claimed |
| US-20220184172-A1 | AMPK/CASPASE-6 AXIS CONTROLS LIVER DAMAGE IN NONALCOHOLIC STEATOHEPATITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-16 | — | — | US | claimed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| US-20250161334-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2025-05-22 | — | — | US | disclosed |
| US-12226478-B2 | Method of treating, reducing, or alleviating a medical condition in a patient | PEYMAN GHOLAM A (US) | 2025-02-18 | — | — | US | disclosed |
| CN-119139283-A | Application of disulfiram in reducing drug resistance of BRAF mutant melanoma targeted drugs and preparation | 中国人民解放军空军军医大学 | 2024-12-17 | — | — | CN | disclosed |
| WO-2024197320-A2 | TARGETING SF3B2 FOR AXONAL PROTECTION IN CENTRAL NERVOUS SYSTEM NEURODEGENERATIVE DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024192340-A2 | TARGETING SF3B2 FOR AXONAL PROTECTION IN CENTRAL NERVOUS SYSTEM NEURODEGENERATIVE DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20220387565-A1 | OCULAR DELIVERY OF CELL PERMEANT THERAPEUTICS FOR THE TREATMENT OF RETINAL EDEMA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-08 | — | — | US | disclosed |
| EP-4087917-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION OF XENOGENEIC ISLET CELLS AND TREATMENT OF INSULIN-RESISTANT OR -DEFICIENT CONDITIONS WITH THE SAME | Hangzhou Qihan Biotechnology Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| US-11446263-B2 | Caspase inhibitor-containing drug for treating or preventing disorders caused by TGF-β, and applications thereof | THE DOSHISHA (JP) | 2022-09-20 | — | — | US | disclosed |
| WO-2022190064-A1 | METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME | VEXO PHARMACEUTICALS DMCC (AE) | 2022-09-15 | — | — | WO | disclosed |
| US-20220202933-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2022-06-30 | — | — | US | disclosed |
| EP-3049530-B1 | METHOD FOR CELL-FREE PROTEIN SYNTHESIS IN THE PRESENCE OF A CASPASE INHIBITOR | FRAUNHOFER GES FORSCHUNG (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-20220184172-A1 | AMPK/CASPASE-6 AXIS CONTROLS LIVER DAMAGE IN NONALCOHOLIC STEATOHEPATITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-16 | — | — | US | disclosed |
| CN-114456243-A | Peanut functional protein AhUB4 and coding gene and application thereof | 广西大学 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024405-A1 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP6, CASP1, CASP3 | CASP3 3/4885CASP1 2/4885CASP9 11/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | CASP3 2526/4885CASP1 1215/4885CASP9 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.